{"name":"AlgiPharma AS","slug":"algipharma-as","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Alginate oligosaccharide","genericName":"Alginate oligosaccharide","slug":"alginate-oligosaccharide","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OligoG Dry powder for inhalation","genericName":"OligoG Dry powder for inhalation","slug":"oligog-dry-powder-for-inhalation","indication":"Cystic Fibrosis (general)","status":"discontinued"}]}],"pipeline":[{"name":"Alginate oligosaccharide","genericName":"Alginate oligosaccharide","slug":"alginate-oligosaccharide","phase":"phase_2","mechanism":"Alginate oligosaccharide works by forming a protective barrier on the surface of the mucosa to treat conditions such as gastroesophageal reflux disease (GERD).","indications":["Gastroesophageal reflux disease (GERD)"],"catalyst":""},{"name":"OligoG Dry powder for inhalation","genericName":"OligoG Dry powder for inhalation","slug":"oligog-dry-powder-for-inhalation","phase":"discontinued","mechanism":"OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways.","indications":["Cystic Fibrosis (general)","Cystic Fibrosis with Burkholderia spp. Infection","Lung Deposition Characterization in Cystic Fibrosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQblQ2eEttMko4Zk1MM0JDdjNXTURkeXRzLTdfLUVxVy1BQmZqZlNkbXd2cVViSDhiX2dybXE0UldoSHdEbjNTa2pwNF9xeWdFMWlSbzlZUEd6RGJ1SHM2OVVWUEpOeG1nbG9vdFlmalp1YzZNd29uT2R6eTZnZkJSbkJ3bmc0Zi1SdEE5OVA5TGlCc2VmSjM4bHV1enJFUFpFY2RsdmJ0dkJxVFJELXcyMDN1bUNaOU1KSHp2cjJKUEwySWxLYWZSWnM0WWxMZDVzSTdOOU15X3BTSUVNVFpEc2FYU1VfQVQ3RjhUcVpPUkprLU1haGkzN291M3JKMTNKNXloU1lZemtFaTh2R1J0VlNTZ0J0U25EQU91QTVsUGc?oc=5","date":"2026-04-07","type":"trial","source":"Business Upturn","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Business Upturn","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1qME13ZF9vWWZDeFpDVG91aUhaeEJKZU5lZFhPdDRLU2YxT2lONmdja0Y4MmxNQ0djNXo3ZXF5UjVFc2F4bGJPMDVmeXdDX1lBM1BsSmxwU1JPWVZ5Y0taTFdyX0p1TXpOQWJ3X3AwNm4?oc=5","date":"2023-05-17","type":"pipeline","source":"Labiotech.eu","summary":"Six Norwegian companies leading the country’s biotech scene - Labiotech.eu","headline":"Six Norwegian companies leading the country’s biotech scene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQYzFkRi1LOG5zMS1RMWJlWVhoanRkejU4TjJGNWJ2MGVxZ3Noc25BUC1CRGFBd3FVbVN3Zi13WFBsUTNiOW5qU1BRdFpaN3JDTU1oazZPV1NSZzN1bTlBeTRoNW1jenNGZFpwVHl0cFlTMHFaOVRFV1lqYVZWSnNBMUhub2NMcDlhVW9mSUt5OEx4aWtDYjI5UTdOcWRFX2w0TTg2cWtn?oc=5","date":"2014-06-21","type":"pipeline","source":"Cystic Fibrosis News Today","summary":"Norwegian Seaweed-based CF Drug Presented at European Conference - Cystic Fibrosis News Today","headline":"Norwegian Seaweed-based CF Drug Presented at European Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNTGpZWnlBUy10cnJXM2QwcTBvUXViWTE4VHVNSlJkWWdGel9CclRkWUdFMGpNQmxYYWxhYllkY1FsdzBPUk1YR3NQdmpzd0otc0szRGJNSWNxcmtsa2FMM21lczV1VDNEeVF1MjQxanZLSnY1S1VoS0dFY3RERmVLZUlUN2hNaUhOb3E4NzFzSFBqNnVfQ0htaUdFRGFvM1pfYnM3RXFYRS1oV2NfSE9KVVJtY3RkSnhsYm83UHZIak5jb0ZvQjJrbjV2UEprZ2NzTGxjN3g0RENiamZpcXdN?oc=5","date":"2014-06-18","type":"pipeline","source":"respiratory-therapy.com","summary":"Seaweed-based Drug Could Extend Life Expectancy for Cystic Fibrosis Patients - respiratory-therapy.com","headline":"Seaweed-based Drug Could Extend Life Expectancy for Cystic Fibrosis Patients - respiratory","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}